Anti-diabetic effects of Ganoderma lucidum

Ma, Haou-Tzong; Hsieh, Jung-Feng; Chen, Shui‐Tein

doi:10.1016/j.phytochem.2015.02.017

Cited by 146 publications

(99 citation statements)

References 49 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although higher concentrations of Li 2 CO 3 , 0.75 and 1.0 mM, significantly decreased the biomass, the Li accumulation exceeded 40 and 60 mg kg −1 dry matter, respectively. The commercial application of Li-enriched G. lucidum may be additionally supported for the medicinal properties of this species, which have long been acknowledged [29,[36][37][38]. Considering that the market for G. lucidum is already worth over 2.5 billion US dollars [39], the commercial introduction of its Li-enriched form should not be troublesome.…”

Section: Discussionmentioning

confidence: 99%

Cultivation of mushrooms for production of food biofortified with lithium

Mleczek

Siwulski

Rzymski

et al. 2016

Eur Food Res Technol

View full text Add to dashboard Cite

investigated mushroom species in various cultures as food or alternative medicines, their Li-biofortified forms could potentially find social acceptance. The concentrations of Li accumulated in fruiting bodies were not high enough for application in psychiatric treatments but could potentially support the daily intake of Li for behavior modification or health beneficiary purposes. Further studies are necessary to fully investigate the safety implications of Li-enriched mushrooms for humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Cultivation of mushrooms for production of food biofortified with lithium

Mleczek

Siwulski

Rzymski

et al. 2016

Eur Food Res Technol

View full text Add to dashboard Cite

show abstract

“…Since then, fungi have been used as traditional Chinese medicines for the prevention or treatment of various chronic diseases [1, 2]. As research on the chemical constituents of these medicinal or edible fungi has increased, there is pre-clinical evidence for G. lucidum in an array of settings including cancer treatment [3–6], diabetic control [7–9], hepato-protection [10–13], antiviral treatment [14], and immune-modulation [15, 16]. …”

Section: Introductionmentioning

confidence: 99%

Cytotoxic lanostane-type triterpenoids from the fruiting bodies ofGanoderma lucidumand their structure-activity relationships

Chen

Yong

et al. 2016

Oncotarget

View full text Add to dashboard Cite

We conducted a study of Ganoderma lucidum metabolites and isolated 35 lanostane-type triterpenoids, including 5 new ganoderols (1-5). By spectroscopy, we compared the structures of these compounds with known related compounds in this group. All of the isolated compounds were assayed for their effect against the human breast carcinoma cell line MDA-MB-231 and hepatocellular carcinoma cell line HepG2. Corresponding three-dimensional quantitative structure–activity relationship (3D-QSAR) models were built and analyzed using Discovery Studio. These results provide further evidence for anti-cancer constituents within Ganoderma lucidum, and may provide a theoretical foundation for designing novel therapeutic compounds.

show abstract

“…The 30-day treatment with the hydroethanolic extract (containing beta-glucan, proteins, and phenols) of G. lucidum fruiting bodies exhibited hypoglycaemic effects in STZ-induced diabetic rats (Bach et al 2018). In addition, many identified bioactive constituents in G. lucidum fruiting bodies, such as polysaccharides, proteoglycans, proteins, ganoderic acids, and triterpenoids, have been shown to exhibit hypoglycaemic activities (Ma et al 2015). Polysacc harides inhibited hyperglycaemia by regulating the expression of several key enzymes in the glucose metabolism pathway, such as hepatic glucokinase, phosphofructokinase, G6PD, hepatic glycogen phosphorylase, fructose-1,6-bisphosphatase, phosphoenolpyruvate carboxykinase, and G6Pase (Xiao et al 2012).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the hypoglycaemic and antioxidant effects of submerged Ganoderma lucidum cultures in type 2 diabetic rats

et al. 2020

View full text Add to dashboard Cite

Tsaihttps://orcid.org/0000-0002-5605-5495 (2020): Evaluation of the hypoglycaemic and antioxidant effects of submerged Ganodermalucidum cultures in type 2 diabetic rats, Mycology, ABSTRACTWe aim to investigate the hypoglycaemic and antioxidant effects of submerged Ganoderma lucidum cultures and elucidate the potential mechanisms behind these effects using a type 2 diabetic rat model. Diabetic rats were daily fed with a high-fat diet supplemented with 1% or 3% freeze-dried whole submerged cultures of G. lucidum or mycelia for 5 weeks. We observed significantly decreased fasting plasma glucose levels, homoeostasis model assessment equationinsulin resistance, and plasma glucose in oral glucose tolerance test. Furthermore, we observed increased levels of glycogen, hepatic hexokinase, glucose-6-phosphate dehydrogenase, and intestinal disaccharidase activities. G. lucidum supplement downregulated the plasma levels of aspartate aminotransferase, alanine aminotransferase, creatinine, and urea nitrogen as well as liver and kidney levels of thiobarbituric acid reactive substances. Based on the hypoglycaemic and antioxidant effects of G. lucidum submerged cultures, we recommend the potential application of these products as functional foods or additives for controlling type 2 diabetes.

show abstract

Anti-diabetic effects of Ganoderma lucidum

Cited by 146 publications

References 49 publications

Cultivation of mushrooms for production of food biofortified with lithium

Cultivation of mushrooms for production of food biofortified with lithium

Cytotoxic lanostane-type triterpenoids from the fruiting bodies ofGanoderma lucidumand their structure-activity relationships

Evaluation of the hypoglycaemic and antioxidant effects of submerged Ganoderma lucidum cultures in type 2 diabetic rats

Contact Info

Product

Resources

About